Canada Markets closed

LexaGene Holdings Inc. (LXXGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4133-0.0115 (-2.71%)
At close: 3:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.4248
Open0.4300
BidN/A x N/A
AskN/A x N/A
Day's Range0.4001 - 0.4300
52 Week Range0.2800 - 1.2200
Volume153,216
Avg. Volume174,033
Market Cap47.266M
Beta (5Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    LexaGene Intends to Pursue Full Panel Pathogen Testing through the FDA

    BEVERLY, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced it intends to pursue both 510k clearance and CLIA-waiver from the FDA to utilize the full potential of the MiQLab System™ for syndromic testing at the point of care. Syndromic testing allows medical providers to simultaneously test patient spec

  • GlobeNewswire

    Leading Veterinary Academic, Dr. Jane Sykes, Joins LexaGene Board of Directors

    BEVERLY, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced Dr. Jane Sykes, BVSc(Hons), PhD, MBA, DipACVIM (Small Animal Internal Medicine) has joined the LexaGene Board of Directors. Dr. Sykes is the Executive Director of Innovation and Entrepreneurship, School of Veterinary Medicine at the University

  • GlobeNewswire

    LexaGene Expands Bio-Pharma Contamination Panel by Adding Test that includes a Biothreat Agent

    BEVERLY, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced it has successfully expanded its bio-pharmaceutical (“bio-pharma”) contamination panel by developing a Burkholderia1 test for use on its MiQLab™ System. Burkholderia cepacia complex, a group of about 24 related environmental bacteria, is a problem contaminant f